Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its infertility portfolio

ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) —  Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended June 30, 2024 and provides a corporate update.

Corporate Highlights from 2Q 2024 to date

  • Company received European Union Medical Device Regulation (EU MDR) certification and CE Mark for four of its women’s health products, providing regulatory approval to begin marketing in the European Union. Further, it serves as independent validation of Femasys’ commitment to the highest standards of quality and safety for its customers and their patients.
  • Femasys completed the build-out of its initial commercial team in the U.S., which will be leading the Company’s marketing efforts. This milestone, together with the CE Mark approval for its product portfolio, enables Femasys to concurrently identify strategic distribution partners to begin commercialization of its products in the European Union.
  • CEO and Founder Kathy Lee-Sepsick met with the White House’s Gender Policy Council to discuss the Company’s reproductive health products and the future of women’s health in the United States and the White House’s Office of Science and Technology Policy to discuss the Cancer Moonshot Initiative, as well as separately with Members of Congress to raise awareness of the Company and our women’s healthcare initiatives.

“The recruitment and subsequent onboarding of our commercial team, consisting of highly qualified professionals with specific expertise in women’s health is complete and our team has recently begun actively marketing our products in the U.S.. We believe that our novel fertility solution FemaSeed®, which demonstrated pregnancy rates more than double the historic intrauterine insemination (IUI) pregnancy rates for male factor infertility (i.e., low sperm count), is an improved alternative and a viable option prior to in vitro fertilization (IVF) that is considerably more financially and emotionally burdensome. As we await announcement of published data for the FemaSeed prospective multi-center pivotal trial, we are actively prioritizing our U.S. efforts and concurrently identifying strategic distribution partners in Europe,” said Femasys’ CEO Kathy Lee-Sepsick.

Financial Results for Quarter Ended June 30, 2024

  • Research and development expenses increased by $448,703 to $1,975,875 in Q2 of 2024 from $1,527,172 in Q2 of 2023.
  • Sales decreased by $99,030 to $221,484 in Q2 of 2024 from $320,514 in Q2 of 2023.
  • Net loss was $4,684,574 or ($0.21) per basic and diluted share attributable to common stockholders, for the quarter ended June 30, 2024, compared to net loss of $2,893,508, or ($0.22) per basic and diluted share attributable to common stockholders, for the quarter ended June 30, 2023.
  • Cash and cash equivalents as of June 30, 2024 was $13.5 million and the Company had an accumulated deficit of $116.7 million. The Company expects, based on its current operating plan, that its existing cash and cash equivalents will be sufficient to fund its ongoing operations into July 2025.

Financial Results for Six Months Ended June 30, 2024

  • Research and development expenses increased by $681,995 to $3,746,606 for the first six months of 2024 from $3,064,611 for the first six months of 2023.
  • Sales decreased by $121,874 to $492,624 for the first six months of 2024 from $614,498 for the first six months of 2023.
  • Net loss was $8,284,084 or ($0.38) per basic and diluted share attributable to common stockholders, for the six month period ended June 30, 2024, compared to net loss of $5,839,765, or ($0.47) per basic and diluted share attributable to common stockholders, for the same period ended June 30, 2023.

For more information, please refer to the Company’s Form 10-Q filed August 8, 2024, which can be accessed on the SEC website.

FEMASYS INC.  
Condensed Balance Sheets  
(unaudited)  
                       
Assets   June 30,
2024
  December 31,
2023
 
Current assets:            
  Cash and cash equivalents $ 13,525,898     21,716,077    
  Accounts receivable, net   92,535     98,906    
  Inventory, net   1,315,580     667,118    
  Prepaid and other current assets   997,623     695,879    
          Total current assets   15,931,636     23,177,980    
Property and equipment, at cost:          
  Leasehold improvements   1,212,417     1,212,417    
  Office equipment   47,308     47,308    
  Furniture and fixtures   429,933     414,303    
  Machinery and equipment   2,599,994     2,559,356    
  Construction in progress   651,157     423,077    
                4,940,809     4,656,461    
Less accumulated depreciation   (3,678,450 )   (3,545,422 )  
          Net property and equipment   1,262,359     1,111,039    
Long-term assets:          
  Lease right-of-use assets, net   2,081,054     2,380,225    
  Intangible assets, net of accumulated amortization   44,317        
  Other long-term assets   957,078     1,086,581    
          Total long-term assets   3,082,449     3,466,806    
          Total assets $ 20,276,444     27,755,825    
(continued)              
                       
FEMASYS INC.  
Condensed Balance Sheets  
(unaudited)  
Liabilities and Stockholders’ Equity   June 30,
2024
  December 31,
2023
 
Current liabilities:          
  Accounts payable $ 951,510     1,137,823    
  Accrued expenses   886,352     1,444,296    
  Clinical holdback – current portion   92,397     65,300    
  Lease liabilities – current portion   533,734     406,636    
          Total current liabilities   2,463,993     3,054,055    
Long-term liabilities:          
  Clinical holdback – long-term portion   32,706     54,935    
  Convertible notes payable, net (including related parties)   4,758,017     4,258,179    
  Lease liabilities – long-term portion   1,771,487     2,036,067    
          Total long-term liabilities   6,562,210     6,349,181    
          Total liabilities   9,026,203     9,403,236    
Commitments and contingencies          
Stockholders’ equity:          
  Common stock, $.001 par, 200,000,000 authorized,          
    22,350,022 shares issued and 22,232,799 outstanding as of        
    June 30, 2024; and 21,774,604 shares issued          
    and 21,657,381 outstanding as of December 31, 2023   22,350     21,775    
  Treasury stock, 117,223 common shares   (60,000 )   (60,000 )  
  Warrants       2,608,642     2,787,137    
  Additional paid-in-capital   125,344,962     123,985,306    
  Accumulated deficit   (116,665,713 )   (108,381,629 )  
          Total stockholders’ equity   11,250,241     18,352,589    
          Total liabilities and stockholders’ equity $ 20,276,444     27,755,825    
                       
FEMASYS INC.        
Condensed Statements of Comprehensive Loss        
(unaudited)          
                Three Months Ended June 30,   Six Months Ended June 30,  
                2024     2023     2024     2023    
Sales         $ 221,484     320,514     492,624     614,498    
Cost of sales (excluding depreciation expense)   73,125     110,469     161,657     215,589    
                               
Operating expenses:                  
  Research and development   1,975,875     1,527,172     3,746,606     3,064,611    
  Sales and marketing   975,190     128,899     1,275,677     373,795    
  General and administrative   1,611,817     1,356,637     3,114,621     2,671,774    
  Depreciation and amortization   67,628     133,299     138,856     266,365    
          Total operating expenses   4,630,510     3,146,007     8,275,760     6,376,545    
          Loss from operations   (4,482,151 )   (2,935,962 )   (7,944,793 )   (5,977,636 )  
Other income (expense):                  
  Interest income   184,138     42,652     408,822     139,741    
  Interest expense   (388,311 )   (198 )   (749,863 )   (1,870 )  
          Total other income (expense), net   (204,173 )   42,454     (341,041 )   137,871    
          Loss before income taxes   (4,686,324 )   (2,893,508 )   (8,285,834 )   (5,839,765 )  
  Income tax benefit   (1,750 )       (1,750 )      
          Net loss $ (4,684,574 )   (2,893,508 )   (8,284,084 )   (5,839,765 )  
                               
Net loss attributable to common stockholders, basic and diluted $ (4,684,574 )   (2,893,508 )   (8,284,084 )   (5,839,765 )  
Net loss per share attributable to common stockholders, basic and diluted $ (0.21 )   (0.22 )   (0.38 )   (0.47 )  
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted   22,215,516     13,107,590     21,995,436     12,493,334    
                               

About Femasys

Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

Forward-Looking Statements 

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. 

Contacts: 

Investors: 
Gene Mannheimer
IR@femasys.com

Media Contact: 
Kati Waldenburg
Media@femasys.com

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

2 days ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago